Goodwin Procter advised Bicara Therapeutics on the deal.Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program BCA101…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
